I just got off the phone with an institutional investor who was long Intercept Pharma (ICPT - Get Report) going into today's big NASH data win. Yes, he's incredibly happy.
He hasn't done a ton of work on obeticholic acid (OCA) in NASH -- he was more focused on the ongoing phase III study in primary billary cirrhosis -- but he has worked through some quick calculations on the commercial potential for OCA in NASH. The numbers are huge and suggest Intercept shares could go even higher. Before that happens, the company could be acquired, he believes.
Yes, he's long Intercept so talking his book to some degree, but hear him out. The story is compelling.
This is the way he looks at the market for OCA in NASH:
2-3% of the U.S. population (315 million people) are diagnosed with NASH, with 0.3% to 0.9% diagnosed with NASH that has progressed to cirrhosis. He uses the latter, sicker patient population for his calculations because they're more likely to seek treatment. This equates to a patient population of 1.8 million people.
Assume Intercept treats 20% of these NASH+cirrhosis patients, which is 360,000 patients.
Assume Intercept prices OCA at $10,000 per year. It's a pill and a daily, chronic treatment, so this pricing is in line with that the PCSK9s might cost.
You're looking at a peak sales potential for OCA in U.S. NASH patients of $3.6 billion.
If you think 20% market share is too high, bring it down to 15%. That's $2.7 billion in peak sales.
How long to $2.7 billion in peak sales? Let's say five years. Sales multiple? 5x. Discount rate: 20%
The net present value of OCA in NASH is $6.75 billion.
Even with today's huge move, Intercept's market cap is $5 billion.
10/14/15 - 11:47 AM EDT
05/19/15 - 04:42 PM EDT
05/19/15 - 12:48 PM EDT
05/18/15 - 08:06 AM EDT
05/05/15 - 02:43 PM EDT
12/01/15 - 08:30 AM EST
12/01/15 - 06:00 AM EST
11/30/15 - 08:30 AM EST
11/30/15 - 01:00 AM EST
11/30/15 - 01:00 AM EST
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.
Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.